This three-center collaborative study was 
microdilution panels for the intralaboratory comparisons. The percentage of strains with minimum inhibitory concentrations in the acceptable range for the interlaboratory variation was 96.2% for the MPS and 96.0% for the reference microdilution panels. The phase II studies used strains with known resistance mechanisms. The percent agreement with these strains was: Enterobacteriaceae, 94.5%; nonenteric gram-negative rods, 95.4%; staphylococci, 92.3%; and streptococci, 96 .6%. The overall agreement within acceptable limits was 94.7% with these strains. When testing 359 clinical isolates, the frequency of strains within the acceptable range of agreement between the two methods was 97.3%. The MPS panels gave results in each of the three study phases equivalent to those obtained with the reference microdilution panels.
The use of a microdilution procedure for the quantitative determination of microbial susceptibility to antimicrobial agents has been studied by a number of investigators (5) (6) (7) (8) 10) . The usage of this methodology has increased with the availability of semiautomated equipment for dispensing the diluted antimicrobial agents in wells of plastic trays. The real increase in the popularity of this methodology has undoubtedly been due to the increasing number of commercial vendors of prepared microdilution trays. These trays contain diluted solutions of antimicrobial agents in the frozen state. The comparatively recent entrance into the market of trays containing different concentrations of antimicrobial agents dried in the wells would provide improved aspects of reproducibility, due in part to their increased shelf life (suggested by the manufacturers to be >12 months). These commercially prepared frozen trays and dried-form products have been evaluated in several studies and found to correlate well with results obtained either with a reference microdilution (RMD) method or with a standardized reference broth dilution method (2, 6, 9, (10) (11) (12) (13) (14) . The Microbial Profile System (MPS; manufactured by Minnesota Mining & Manufacturing Co. [3M Co.], St. Paul, Minn.) is a microdilution tray containing dried reagents for biochemical identification and serial concentrations of antimicrobial agents for susceptibility testing. We present a three-center evaluation of the panel containing the dried antimicrobial agents to determine the comparative accuracy and reproducibility of these panels for determining the minimum inhibitory concentrations (MICs) of the agents dried in the tray. Standardized reference methods were utilized for these comparisons (12) . MATERIALS In phase III of the study, a collaborative evaluation of the antimicrobial susceptibility testing of recent clinical isolates with the MPS and with the RMD was done at three medical centers. A total of 359 bacterial isolates were tested by each method. The strains were all recent isolates (i.e., less than 48 h), and they were to have been selected so that the collection would not include more than 25% E. coli and no more than 15% S. aureus. As can be seen from footnote a in Table 9 , this percentage was met, thereby providing a good distribution of test species. The test strains were identified to the species level by either the API system or a comparable method (4) . Organisms susceptible and resistant to each tested antimicrobial agent were found in the study population.
The results of the comparison studies with the clinical isolates are shown in Tables 9 and 10 . Of the 1,538 on-scale data pairs, 97.3% of the ratios were in the accepted ratios (0.5, 1, and 2) for comparative evaluation. If the total 4,536 pairs, which would represent both on-and off-scale values, were considered, only 2.6% of those values were off-scale. (10, 11, 11) , Proteus (17, 10, 10), Serratia (5, 6, 2), Citrobacter (1, 3, 7) , Providencia (0, 0, 3), Aeromonas (2, 0, 0), Pseudomonas (10, 13, 9), Acinetobacter (5, 0, 0), Staphylococcus (32, 22, 10), and Streptococcus (16, 11, 20) . The 41 strains with MIC ratios that were outside of the acceptable limits (ratios of c0.25 and .4) represented only 2.7% of the total onscale ratios. These accounted for only 0.5% very major interpretive errors (false-sensitive MICs by the MPS method). The antimicrobial agentorganism combinations resulting in these very major errors were: oxacillin, S. aureus; ampicillin, S. marcescens; ampicillin, M. morganii; ampicillin, P. rettgeri; gentamicin, P. aeruginosa; aminoglycosides, A. calcoaceticus subsp. anitratus (2 strains); and chloramphenicol, K. pneumoniae. Changes in the interpretive criteria did not occur when the MIC ratios were within the acceptable limits.
The results with nalidixic acid and nitrofurantoin also were not included in the overall percent agreement because only off-scale MIC ratios of 1.0 were possible since these were tests of single concentrations of either drug. Even when added to the total results, they increased the acceptable totals by <1.0%. Therefore, 97.3% of all tests were in acceptable agreement.
The occurrence of a well with growth of the test organisms that is preceded and followed by wells in which growth has been inhibited is referred to as the skipped-well phenomenon (5, 8, 9) . This phenomenon occurred frequently in the MPS panels; e.g., 106 and 142 incidents in phase II and phase III, respectively. The majority of incidents occurred when testing the aminoglycosides in the Kaiser and U.C. Davis laboratories. In both laboratories, the problem occurred only in the wells designated as containing the highest concentrations of amikacin, gentamicin, or kanamycin. The U.C. Davis laboratory assayed the aminoglycoside content of the wells in the gram-negative MPS trays and found that many of the high-concentration wells did not contain any detectable drug. The St. Francis laboratory had noticed a similar occurrence (in earlier product development) in the wells containing the lowest concentrations of penicillin G. The St. Francis laboratory subsequently assayed all the wells in three lots of trays and found that the antimicrobial agent content was consistently between 90 and 102% of the designated content. This variation is within the acceptable range of variation for such products. The trays in a fourth production lot of gramnegative panels were assayed for the well content of aminoglycoside by bioassay, high-performance liquid chromatography, and fluorescent immunoassay methods (1). The aminoglycoside content was consistently within 10% of the stated value.
DISCUSSION
The accuracy and reproducibility of MIC results obtained with the MPS trays were tested in three participating laboratories. This comparative evaluation was made by using single lots of RMD trays produced in the laboratories of each participating investigator (12) . The MIC ratios were within the acceptable range (indicating results in the range of ±1 log2 dilution concentration) for 95.9, 96.3, and 97.3% for two groups of stock cultures (phase I and II) and 359 recent clinical isolates (phase III), respectively. The MPS-MIC/RMD-MIC ratios for the stock and challenge strains compared favorably with those obtained with the Sensititre and Sceptor systems, both of which contain antimicrobial agents in a dried form (6, 9, 10) . The results from all three studies show better agreement than those from a commercially prepared frozen tray (2, 6, 9, 10). The intralaboratory and interlaboratory reproducibility of the MPS trays was acceptable for all three laboratories. The results were most similar to those obtained with the RMD method. The intralaboratory variation outside of the acceptable range was only 4.1 and 3.7% for the two groups of stock strains and 2.7% for the recent clinical isolates.
The MPS and RMD methods both accurately categorized the resistant and susceptible strains within the various bacterial genera and species. There were notably lower aminoglycoside MPS MIC results when testing enterococci, but this was not considered a significant clinically relevant problem, as those organisms are not effectively treated by aminoglycosides alone. A low incidence (<0.5%) of very major MPS interpretive errors was found in all study phases. This was especially evident when testing beta-lactamase-producing Enterobacteriaceae and the aminoglycoside-resistant enteric and nonfermentative gram-negative bacilli. The MPS results with methicillin-resistant staphylococci were inconsistent compared with the other antimicrobial agents. These results indicate that oxacillin is not an optimal reagent for detecting methicillin resistance of staphylococci; however, more studies on this subject are required.
The occurrence of the skipped-well phenomenon in commercial dry-form products has been reported by others (5, 9; R. Jones, manuscript in preparation). An earlier report by Jones and colleagues offered reasonable explanations of this infrequent problem (9) . In this study, however, the high frequency of skipped wells was explained by the findings of antimicrobial agentfree wells. This problem was mechanical and limited to the high-concentration wells of amikacin, gentamicin, and kanamycin. The assays of subsequent MPS production lots showed appropriate concentrations of antimicrobial agents in each well, indicating that this problem has been eradicated.
MPS is the fourth dry-form product to be evaluated. The first product, the AST, was evaluated by MacLowry and Marsh (11) and Tilton and Isenberg (13) . In the report by Tilton and Isenberg, they cited approximately 90% correlation of AST susceptibility results with those of the disk diffusion, agar dilution, and broth microdilution methods. The continued excellent accuracy of other products containing dried antimicrobial agents indicates that this methodology should be readily accepted by clinical laboratories. The minor disadvantages encountered in rehydrating the trays are vastly outweighed by conveniences such as long shelf life (>12 months) and room temperature storage. These trays also allow laboratories to use several broth media and to routinely use cationsupplemented Mueller-Hinton broth, which is generally unavailable in the frozen trays (12) . This latter capability is provided in the unique medium found in the Sceptor system (9) .
We conclude that the MPS for broth microdilution antimicrobial agent susceptibility testing gives MICs equivalent to those of the National Committee for Clinical Laboratory Standards reference broth microdilution method (12) . The complete MPS system contains dried reagents for simultaneous biochemical identification and antimicrobial susceptibility testing. This capability should provide a significant reduction in labor and an increased capability for data handling, thus providing more accurate laboratory reports and an epidemiological system of biotypes and antibiograms previously available only by extended effort on the part of laboratory personnel. The accuracy of the MPS biochemical system has yet to be reported.
